Další formáty:
BibTeX
LaTeX
RIS
@proceedings{2327137,
author = {Obermannová, Radka and Selingerová, Iveta and Demlová, Regina and Valík, Dalibor and Zdražilová Dubská, Lenka and Kiss, Igor},
doi = {http://dx.doi.org/10.1016/j.annonc.2023.04.432},
keywords = {COVID-19; Solid cancer; multicentric trial;},
language = {eng},
title = {CoVigi phase IV multicentric trial evaluating COVID-19 vaccination effectiveness, safety, and immune response dynamics: SARS-CoV-2-specific antibody and T-cell response focused on patients with gastrointestinal tumors},
url = {https://www.sciencedirect.com/science/article/pii/S0923753423005744?via%3Dihub},
year = {2023}
}
TY - CONF
ID - 2327137
AU - Obermannová, Radka - Selingerová, Iveta - Demlová, Regina - Valík, Dalibor - Zdražilová Dubská, Lenka - Kiss, Igor
PY - 2023
TI - CoVigi phase IV multicentric trial evaluating COVID-19 vaccination effectiveness, safety, and immune response dynamics: SARS-CoV-2-specific antibody and T-cell response focused on patients with gastrointestinal tumors
KW - COVID-19
KW - Solid cancer
KW - multicentric trial;
UR - https://www.sciencedirect.com/science/article/pii/S0923753423005744?via%3Dihub
N2 - Solid cancer patients are at high risk of a more severe course of COVID-19, especially those undergoing active anti-cancer therapy causing immunosuppression. Vaccination is still the only option to prevent serious events associated with SARS-CoV-2 infection. We aim to assess adverse effects, efficacy, and immune response against SARS-CoV-2 in cancer patients, focusing on comparison with healthy volunteers and possible interfering therapy.
ER -
OBERMANNOVÁ, Radka, Iveta SELINGEROVÁ, Regina DEMLOVÁ, Dalibor VALÍK, Lenka ZDRAŽILOVÁ DUBSKÁ a Igor KISS. \textit{CoVigi phase IV multicentric trial evaluating COVID-19 vaccination effectiveness, safety, and immune response dynamics: SARS-CoV-2-specific antibody and T-cell response focused on patients with gastrointestinal tumors}. 2023. Dostupné z: https://dx.doi.org/10.1016/j.annonc.2023.04.432.
|
